 | Zacks: Brokerages Expect ContraFect Corp (NASDAQ:CFRX) Will Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - February 27 at 5:50 PM |
| Short Interest in ContraFect Corp (NASDAQ:CFRX) Decreases By 64.1%
www.americanbankingnews.com - February 26 at 11:02 PM |
 | Form 8-K CONTRAFECT Corp For: Feb 24 - StreetInsider.com
www.streetinsider.com - February 25 at 8:25 AM |
 | Health Care Sector Update for 02/24/2020: ENLV, CFRX, UTHR, JNJ, PFE, ABT, MRK, AMGN - Nasdaq
www.nasdaq.com - February 24 at 7:41 PM |
| ContraFect's (CFRX) Buy Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - February 24 at 3:29 PM |
 | BRIEF-Contrafect Announces FDA's Breakthrough Therapy Designation To Exebacase - Reuters
www.reuters.com - February 24 at 2:41 PM |
| ContraFect (CFRX) Gratned FDA Breakthrough Therapy Designation to Exebacase for the Treatment of MRSA Bacteremia, Including Right-Sided Endocarditis - StreetInsider.com
www.streetinsider.com - February 24 at 8:37 AM |
 | ContraFect +14% premarket on BTD tag for exebacase - Seeking Alpha
seekingalpha.com - February 24 at 8:37 AM |
 | ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis - Yahoo Finance
finance.yahoo.com - February 24 at 8:37 AM |
| ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
finance.yahoo.com - February 24 at 8:37 AM |
| BRIEF-ContraFect Says Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing Rule
www.reuters.com - February 23 at 8:10 AM |
| BRIEF-ContraFect Says Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing Rule - Reuters
www.reuters.com - February 21 at 11:57 PM |
| CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway… - Yahoo Finance
finance.yahoo.com - February 18 at 6:14 PM |
| CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…
finance.yahoo.com - February 18 at 6:13 PM |
| ContraFect Corp (NASDAQ:CFRX) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - February 17 at 6:14 PM |
| CollPlant Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors - Yahoo Finance
finance.yahoo.com - February 10 at 6:35 PM |
| ContraFect: A Game-Changing Treatment For The Superbug MRSA - Seeking Alpha
seekingalpha.com - February 10 at 6:35 PM |
| Zacks: Brokerages Anticipate ContraFect Corp (NASDAQ:CFRX) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 5 at 6:46 AM |
| ContraFect Announces One-for-Ten Reverse Stock Split - Yahoo Finance
finance.yahoo.com - February 4 at 6:20 PM |
 | ContraFect Announces One-for-Ten Reverse Stock Split - GlobeNewswire
www.globenewswire.com - February 4 at 8:02 AM |
| ContraFect (CFRX) Announces 1-for-10 Reverse Stock Split - StreetInsider.com
www.streetinsider.com - February 4 at 8:02 AM |
| ContraFect Announces One-for-Ten Reverse Stock Split
finance.yahoo.com - February 4 at 8:02 AM |
| ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology - GlobeNewswire
www.globenewswire.com - February 3 at 9:21 AM |
| ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
finance.yahoo.com - February 3 at 9:21 AM |
| ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Yahoo Finance
finance.yahoo.com - January 27 at 1:15 PM |
| ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - GlobeNewswire
www.globenewswire.com - January 27 at 7:37 AM |
| ContraFect to Present at 2020 ASM Biothreats - Yahoo Finance
finance.yahoo.com - January 22 at 5:40 PM |
| ContraFect to Present at 2020 ASM Biothreats
finance.yahoo.com - January 22 at 5:40 PM |
| CFRX: Phase 3 DISRUPT Trial Underway… - Yahoo Finance
finance.yahoo.com - January 21 at 3:56 PM |
| CFRX: Phase 3 DISRUPT Trial Underway…
finance.yahoo.com - January 21 at 3:56 PM |
| ContraFect Corporation Is A Differentiated Infectious Disease Pick For 2020 - Seeking Alpha
seekingalpha.com - January 16 at 8:09 AM |
| ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections - Yahoo Finance
finance.yahoo.com - January 13 at 8:22 PM |
| ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections - GlobeNewswire
www.globenewswire.com - January 13 at 8:39 AM |
| ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
finance.yahoo.com - January 13 at 8:39 AM |
| ContraFect commences late-stage study of exebacase; shares up 8% premarket - Seeking Alpha
seekingalpha.com - January 10 at 8:19 PM |
| ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - Yahoo Finance
finance.yahoo.com - January 10 at 3:16 PM |
| ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
finance.yahoo.com - January 10 at 3:16 PM |
 | January Is Often a Big Month for Biotech Mergers and Acquisitions - Barron's
www.barrons.com - January 8 at 4:44 PM |
| ContraFect to Present at Biotech Showcase 2020 Nasdaq:CFRX - GlobeNewswire
www.globenewswire.com - January 6 at 9:48 PM |
| Pfizer Bought Penny Biotech Stock ContraFect Just Before It Doubled - Barron's
www.barrons.com - January 4 at 7:58 AM |
| Pfizer Bought a Penny Biotech Stock Just Before It Doubled
finance.yahoo.com - January 4 at 7:58 AM |
| Form PRE 14A CONTRAFECT Corp For: Jan 31 - StreetInsider.com
www.streetinsider.com - December 27 at 6:52 PM |
| Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)? - Yahoo Finance
finance.yahoo.com - December 20 at 1:54 PM |
| Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)?
finance.yahoo.com - December 20 at 1:54 PM |
| ContraFect (CFRX) Commences Pivotal Phase 3 DISRUPT Study of Exebacase as Treatment for Staph Aureus Bacteremia, Including Right-Sided Endocarditis - StreetInsider.com
www.streetinsider.com - December 20 at 8:53 AM |
| ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - GlobeNewswire
www.globenewswire.com - December 20 at 8:53 AM |
| ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
finance.yahoo.com - December 20 at 8:53 AM |
| ContraFect (CFRX) Announces First Gram-negative Product Candidate CF-370, Direct Lytic Agent Targeting Pseudomonas aeruginosa - StreetInsider.com
www.streetinsider.com - December 19 at 8:06 AM |
| ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa - GlobeNewswire
www.globenewswire.com - December 18 at 8:45 AM |
| ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
finance.yahoo.com - December 18 at 8:45 AM |
